Um estudo aberto de escalonamento de dose para avaliar XmAb24306 como agente único e em combinação com atezolizumabe em participantes com tumores sólidos localmente avançados ou metastáticos

Key General Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Life expectancy >/= 12 weeks
• Adequate hematologic and end-organ function
• For participants receiving therapeutic anticoagulation: stable anticoagulant regimen
• Negative serum pregnancy test for women of childbearing potential
• Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Availability of representative tumor specimens

Key General Exclusion Criteria

• Pregnant or breastfeeding, or intending to become pregnant during the study
• Significant cardiovascular disease
• Current treatment with medications that prolong the QT interval
• Known clinically significant liver disease
• Poorly controlled Type 2 diabetes mellitus
• Symptomatic, untreated, or actively progressing CNS metastases
• History of leptomeningeal disease
• History of malignancy other than disease under study within 3 years prior to screening
• Active or history of autoimmune disease or immune deficiency
• Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection
• Positive for HIV infection
• Prior allogeneic stem cell or solid organ transplantation